Barclays lowered the firm’s price target on Mirati Therapeutics to $71 from $75 and keeps an Overweight rating on the shares. The analyst says the European Medicines Agency’s negative opinion on Krazati will have a minimal impact. The firm still sees a high probability of second-line lung cancer approval.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati announces EMA’s CHMP issued negative opinion on MAA for KRAZATI
- Mirati Therapeutics price target lowered to $42 from $51 at Morgan Stanley
- Mirati Therapeutics: JOCO publishes results from KRYSTAL-1 study of adagrasib
- Oppenheimer Sees Over 50% Gains in These 2 Stocks — Here’s Why They Could Soar